Valted Seq Acquires Rights to Develop Biomarker Assays

Valted Seq Acquires Rights to Develop Biomarker Assays

293590

Valted Seq Acquires Rights to Develop Biomarker Assays

D&D Pharmatech’s new subsidiary, Valted Seq, announced it has acquired exclusive rights from Johns Hopkins University to develop multiple biomarker assays for the evaluation and management of neurodegenerative diseases, including Parkinson’s. “There are currently no clinically accepted biomarker assays available for Parkinson’s disease. An assay capable of identifying disease-relevant biomarker results would provide high medical value to these patients,” Seulki Lee, PhD, chairman of Valted Seq, said in a press release. Two types of assays…

You must be logged in to read/download the full post.